A5057009089- Inflammatory Bowel Disease
- Microscopic Colitis
- Chronic Kidney Disease and Diabetes
- Bone health and treatments
- Metabolism, Diabetes, and Cancer
- Spondyloarthritis Studies and Treatments
- Liver Disease Diagnosis and Treatment
- Eosinophilic Esophagitis
- Diabetes Treatment and Management
- Bone health and osteoporosis research
- Frailty in Older Adults
- Hepatitis B Virus Studies
- Cytomegalovirus and herpesvirus research
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Dialysis and Renal Disease Management
- SARS-CoV-2 and COVID-19 Research
- Lipid metabolism and disorders
- Healthcare Policy and Management
- Diabetes Management and Research
- Healthcare cost, quality, practices
- Psoriasis: Treatment and Pathogenesis
- Biosimilars and Bioanalytical Methods
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes and associated disorders
University of Messina
2014-2023
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
2020-2021
Biologically naïve patients with inflammatory bowel disease treated vedolizumab (VDZ) are largely underrepresented in real-world cohorts. A multi-centre, observational cohort study was performed on the effectiveness and safety of VDZ biologically subjects Crohn's (CD) ulcerative colitis (UC).Data consecutive CD UC from July 2016 to December 2019 were extracted Sicilian Network for Inflammatory Bowel Disease.A total 172 (CD: N = 88; UC: 84; median age 66.0 years) included, a follow-up 58.8...
Ustekinumab is approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Italian real-life data are scarce, so aim this study was assess effectiveness and safety ustekinumab an cohort CD patients.Data patients with who started using were extracted from Sicilian Network Inflammatory Bowel Disease. Primary end-points steroid-free clinical remission at 8, 24, 52 weeks therapy reduction C-reactive protein. Secondary response, persistence 12 months, safety.A total 131...
Abstract Background and Aims Older patients with ulcerative colitis treated tofacitinib are at risk for major cardiovascular events, thromboembolism, herpes zoster, malignancies and, accordingly, its use is limited by the regulatory authorities. The aim of present study was to evaluate occurrence adverse events potential preventive measures. Methods We retrospectively evaluated tofacitinib, divided into two groups according comorbidities age. Patient- disease-related variables were recorded...
Background. Screening-based CKD estimates may not provide a sufficient insight into the impact of on use healthcare resources in clinical practice. The aim this study was to evaluate epidemiology “medicalized” CKD, that is, requiring services, an outpatient setting. Design, Setting, Participants, and Measurements. This is retrospective, longitudinal population-based conducted large general practice setting Southern Italy (Caserta) using database. Over 2006–2011, all patients with diagnosis,...
The effectiveness of Ustekinumab (UST) on Crohn's disease (CD)-associated spondyloarthropathy (SpA) is currently unknown.All consecutive CD patients with active SpA at the initiation treatment UST were extracted from cohort Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). primary outcome was articular response 8 and 24 weeks, defined as disappearance objective signs arthritis (swelling and/or stiffness) resolution pain.Thirty assessed. At 13 (43.3%) had an response, including 10/18...
Inflammatory bowel diseases (IBDs) are characterized by a multifactorial clinical picture, in which age-related physical, functional and psychological symptoms may coexist. The accurate evaluation identification of such symptomatology acquires considerable importance the context older adults, since those core factors typical IBD also expose patients to an increased risk for negative outcomes, as frailty disability. purpose present review was provide updated overview on management elderly...
New therapeutic approaches for ulcerative colitis (UC) are now available, but there is still no robust evidence predictors of poor outcomes. We aimed to evaluate the factors associated with a chronic active UC disease course.Data all outpatients followed at least 3 years after diagnosis between 2005 and 2018 were retrospectively collected. The primary aim was identify risk diagnosis. Moreover, following variables investigated: proximal extension or regression, proctocolectomy, early use...
Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia. The availability of new antidiabetic drugs (ADs) has led to complex treatment patterns and changes in the specific drug utilization. aim this population-based study was describe pattern use Southern Italy years 2011–2017, relation updated type 2 diabetes (T2DM) therapy guidelines. A retrospective cohort conducted on T2DM patients using data from Palermo Local Health Unit (LHU) claims database diabetologist...
Background Diagnostic delay in IBD is a major problem and diagnosis frequently arrived when irreversible damage has already occurred. This study evaluated accuracy of faecal calprotectin (fCAL) integrated with diagnostic criteria for early primary care setting.Methods General practitioners (GPs) were trained to recognize alarm symptoms classified as minor criteria. Fulfilment one or at least two was followed by free fCAL testing visit an specialist follow-up over 12 months. All patients...
Background Adherence to vaccinations is unsatisfactory in the inflammatory diseases (IBD) population because of concerns regarding adverse events or low perception infectious risk. The aim this study was maximise adherence anti-Covid-19 vaccination IBD patients. Methods In third trimester 2020, all patients were informed concerning need for and family physicians advised proceed with anti-Influenza anti-pneumococcus vaccinations. Demographic data, disease-related data together acceptance...
Abstract Background Biologic-naïve patients treated with Vedolizumab (VDZ) are largely underrepresented in real-world cohorts. We performed a multicentre, observational, cohort study on the effectiveness and safety of VDZ as treatment for Crohn’s disease (CD) ulcerative colitis (UC) among biologic-naïve subjects. Methods Data consecutive CD UC from July 2016 to December 2019 were extracted Sicilian Network Inflammatory Bowel Disease (SN-IBD). The primary outcome was clinical response at 14...
Identification of asymptomatic hepatitis B virus (HBV) and C (HCV) carriers is fundamental to reach the World Health Organization objective eradicate viral hepatitis. The aim this study was evaluate HBV HCV prevalence among patients hospitalized for a non-liver-related disease but showing increased liver enzyme values.All consecutive without history hepatic amino-transferase and/or gamma-glutamil-transpeptidase levels at admission Internal Medicine Surgery divisions Messina University...
Abstract Background The efficacy of Ustekinumab (UST) on Crohn’s disease (CD) associated spondyloarthropathy (SpA) was evaluated neither in randomized controlled trials nor real-world studies. Web-based data from the cohort Sicilian Network for Inflammatory Bowel Disease (SN-IBD) were extracted to perform a multicentre, assessment effectiveness UST CD-associated SpA Methods All consecutive CD patients with active at initiation treatment January 2019 (the date which drug became available...